Skip to main content
. 2022 Jun 16;3(5):526–535. doi: 10.1016/j.hroo.2022.06.004

Table 1.

Subject characteristics and medical history

US subjects (n = 56) European subjects (n = 57) Japanese subjects (n = 30) All subjects (n = 143) P value
Age, y, mean ± SD (n) 63.4 ± 9.8 (56) 60.7 ± 10.9 (57) 62.6 ± 13.0 (30) 62.2 ± 10.9 (143) .4245
Sex, % (n/N)
 Female 48.2% (27/56) 28.1% (16/57) 16.7% (5/30) 33.6% (48/143) .0067
 Male 51.8% (29/56) 71.9% (41/57) 83.3% (25/30) 66.4% (95/143) .0067
BMI, mean ± SD (n) 32.3 ± 6.7 (56) 27.0 ± 3.6 (57) 23.9 ± 3.1 (30) 28.4 ± 6.0 (143) <.0001
History of other arrhythmia, % (n/N) 42.9% (24/56) 19.3% (11/57) 16.7% (5/30) 28.0% (40/143) .0061
Atrial flutter 28.6% (16/56) 15.8% (9/57) 13.3% (4/30) 20.3% (29/143) .1362
Atrial tachycardia 5.4% (3/56) 0.0% (0/57) 0.0% (0/30) 2.1% (3/143) .0925
Ventricular tachycardia 10.7% (6/56) 1.8% (1/57) 0.0% (0/30) 4.9% (7/143) .0330
Heart block or atrioventricular dysfunction 12.5% (7/56) 3.5% (2/57) 3.3% (1/30) 7.0% (10/143) .1169
History of hypertension, % (n/N) 75.0% (42/56) 43.9% (25/57) 53.3% (16/30) 58.0% (83/143) .0030
History of any procedure to occlude or close the left atrial appendage, % (n/N) 0.0% (0/56) 0.0% (0/57) 0.0% (0/30) 0.0% (0/143) n/a
History of class I/III AAD, % (n/N) 89.3% (50/56) 84.2% (48/57) 73.3% (22/30) 83.9% (120/143) .1581
Pacemaker or implantable cardiac monitor, % (n/N) 1.8% (1/56) 1.8% (1/57) 0.0% (0/30) 1.4% (2/143) .7639
Left atrial diameter (cm) 4.0 ± 0.6 (54) 3.9 ± 0.8 (36) 3.6 ± 0.6 (24) 3.9 ± 0.7 (114) .0317

AAD = antiarrhythmic drugs; BMI = body mass index; n/a = not applicable.

P-value from 1-way analysis of variance for continuous variables and χ2 test for categorical variables.